ORIC vs ZYME

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 10, 2026

ORIC

53.0
AI Score
VS
ORIC Wins

ZYME

50.9
AI Score

Investment Advisor Scores

ORIC

53score
Recommendation
HOLD

ZYME

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ORIC ZYME Winner
Net Income -77.26M -81.13M ORIC
Operating Income -84.92M -92.55M ORIC
ROE -20.3% -30.2% ORIC
ROA -19.1% -23.4% ORIC
Total Assets 404.69M 346.53M ORIC
Cash 37.48M 41.16M ZYME
Current Ratio 13.19 5.88 ORIC
Free Cash Flow -64.40M -34.53M ZYME

Relative Price Performance (Last 90 Days)

ORIC 1M: -12.4% · 3M: +54.0% ZYME 1M: +5.3% · 3M: +14.3%

Current Technical Phase

ORIC

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 41

RSI (14): 40.9 · Price: $12.04

ZYME

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 45

RSI (14): 45.5 · Price: $26.24

Fundamentals Snapshot

Metric ORIC ZYME
Market Cap
Forward P/E -7.5 22.5
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% -0.9%
Gross Margin -2.5%
Operating Margin 0.0% -9.2%
EPS -1.26 -2.02
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ORIC is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.